Our Mission
We protect the genome.
Permanence Bio creates medicine that shields DNA from the damage behind aging, disease, and cancer.
Our Mission
We protect the genome.
Permanence Bio creates medicine that shields DNA from the damage behind aging, disease, and cancer.
Early Damage
Most disease begins as damage.
It starts long before anyone detects it. Year after year, our DNA takes on damage that drives mutation and, in time, cancer. By the time it shows up, it’s hard to treat.
Early Damage
Most disease begins as damage.
It starts long before anyone detects it. Year after year, our DNA takes on damage that drives mutation and, in time, cancer. By the time it shows up, it’s hard to treat.
Early Action
We stop damage from becoming disease.
We act while the damage is still happening, before it becomes harmful. We screen at scale, then use AI to find therapies that stabilize the genome.
Early Action
We stop damage from becoming disease.
We act while the damage is still happening, before it becomes harmful. We screen at scale, then use AI to find therapies that stabilize the genome.
Today
Today
Initial applications show our science at work today.
Initial applications show our science at work today.
Two programs are already helping protect DNA from damage, each a building block for more advanced applications ahead.
Two programs protect from DNA damage today. Each is a building block for future, more complex applications.
Two programs protect from DNA damage today. Each is a building block for future, more complex applications.
01
Radiation Protection
Shielding the immune system and gut lining from acute radiation exposure, in emergencies and high-risk work.
02
Safer Cancer Treatment
Protecting kidneys, salivary glands, and bone marrow so patients can better tolerate powerful radioligand therapies.
01
Radiation Protection
Shielding the immune system and gut lining from acute radiation exposure, in emergencies and high-risk work.
01
Radiation Protection
Shielding the immune system and gut lining from acute radiation exposure, in emergencies and high-risk work.
02
Safer Cancer Treatment
Protecting kidneys, salivary glands, and bone marrow so patients can better tolerate powerful radioligand therapies.
02
Safer Cancer Treatment
Protecting kidneys, salivary glands, and bone marrow so patients can better tolerate powerful radioligand therapies.
Tomorrow
A cancer we intercept.
Follow the same idea far enough, and it points somewhere bigger: intercepting cancer at its start, before it ever becomes a diagnosis.
Permanence Bio creates medicine that shields DNA from the damage behind aging, disease, and cancer, so more people stay well, longer.
Team
Team
The people behind Permanence Bio.
The people behind Permanence Bio.
permanence bio is led by scientists trained in DNA damage, with advisors across chemistry, longevity, and cancer research.
permanence bio is led by scientists trained in DNA damage, with advisors across chemistry, longevity, and cancer research.
Our Team
Our Team
Alan Tomusiak, PhD
CEO
After earning his degree from Stanford University, Alan developed a deep passion for addressing aging and cancer prevention. He studied age-associated diseases through a PhD at the Buck Institute before founding Permanence Bio to translate these insights into therapies.
Alan Tomusiak, PhD
CEO
After earning his degree from Stanford University, Alan developed a deep passion for addressing aging and cancer prevention. He studied age-associated diseases through a PhD at the Buck Institute before founding Permanence Bio to translate these insights into therapies.
Carlos Galicia, PhD
Director of Research
Carlos has long been interested in how aging limits human potential. As an undergraduate at Idaho, he studied CNS regeneration, then earned a PhD in the Biology of Aging at the Buck Institute. Now, as Director of Research at Permanence Bio, he builds systems to discover cancer-preventing compounds.
Carlos Galicia, PhD
Director of Research
Carlos has long been interested in how aging limits human potential. As an undergraduate at Idaho, he studied CNS regeneration, then earned a PhD in the Biology of Aging at the Buck Institute. Now, as Director of Research at Permanence Bio, he builds systems to discover cancer-preventing compounds.
Eddie Anderton, PhD
Head of Development
Eddie was drawn to longevity, believing aging is our era's most pressing medical problem. He studied Biochemistry at Oxford, then earned a PhD in Aging Biology at the Buck Institute. Now, Head of Development at Permanence Bio, he is spearheading the advancement of lead compounds through IND-enabling studies into the clinic.
Eddie Anderton, PhD
Head of Development
Eddie was drawn to longevity, believing aging is our era's most pressing medical problem. He studied Biochemistry at Oxford, then earned a PhD in Aging Biology at the Buck Institute. Now, Head of Development at Permanence Bio, he is spearheading the advancement of lead compounds through IND-enabling studies into the clinic.
Katrina Mae Reyes
Computational Scientist
During her time at UCLA, Katrina researched cancer immunology—how cytokines impact the tumor microenvironment in colorectal cancer. She earned a master's in molecular science and software engineering from UC Berkeley. Now, at Permanence Bio, she builds and validates the AI platform that creates Permanence Bio's compounds.
Katrina Mae Reyes
Computational Scientist
During her time at UCLA, Katrina researched cancer immunology—how cytokines impact the tumor microenvironment in colorectal cancer. She earned a master's in molecular science and software engineering from UC Berkeley. Now, at Permanence Bio, she builds and validates the AI platform that creates Permanence Bio's compounds.
Advisors
Advisors
Jim Frederich, PhD
Chemistry Advisor
An expert in the intersection of organic chemistry and cancer, Dr. Jim Frederich and his laboratory at Florida State University are working with Permanence Bio to develop the next generation of therapeutics for preventing damage to the genome.
READ BIO
Jim Frederich, PhD
Chemistry Advisor
An expert in the intersection of organic chemistry and cancer, Dr. Jim Frederich and his laboratory at Florida State University are working with Permanence Bio to develop the next generation of therapeutics for preventing damage to the genome.
READ BIO
Eduardo Vilar-Sanchez, MD, PhD
Clinical Advisor
Dr. Vilar-Sanchez is a physician-scientist at MD Anderson Cancer Center specializing in hereditary cancer syndromes and cancer prevention. His work on Lynch syndrome and DNA repair mechanisms helps shape the company’s clinical strategy.
READ BIO
Eduardo Vilar-Sanchez, MD, PhD
Clinical Advisor
Dr. Vilar-Sanchez is a physician-scientist at MD Anderson Cancer Center specializing in hereditary cancer syndromes and cancer prevention. His work on Lynch syndrome and DNA repair mechanisms helps shape the company’s clinical strategy.
READ BIO
Sir John Burn, MD
Clinical Advisor
A global leader in cancer prevention, Sir John Burn has over two decades of experience conducting trials in Lynch Syndrome. His expertise in translational medicine is instrumental in guiding the company’s approach to early intervention.
READ BIO
Sir John Burn, MD
Clinical Advisor
A global leader in cancer prevention, Sir John Burn has over two decades of experience conducting trials in Lynch Syndrome. His expertise in translational medicine is instrumental in guiding the company’s approach to early intervention.
READ BIO
Vera Gorbunova, PhD
Scientific Advisor
Dr. Gorbunova is a leader in aging and cancer resistance research. Her work on DNA repair in long-lived species provides valuable insights into new approaches for reducing cancer risk at the cellular level.
READ BIO
Vera Gorbunova, PhD
Scientific Advisor
Dr. Gorbunova is a leader in aging and cancer resistance research. Her work on DNA repair in long-lived species provides valuable insights into new approaches for reducing cancer risk at the cellular level.
READ BIO
Winfried Edelmann, PhD
Scientific Advisor
Dr. Edelmann is an expert in DNA mismatch repair and its role in cancer susceptibility. His foundational research has been critical in understanding how genomic instability drives cancer, helping inform the company’s therapeutic development.
READ BIO
Winfried Edelmann, PhD
Scientific Advisor
Dr. Edelmann is an expert in DNA mismatch repair and its role in cancer susceptibility. His foundational research has been critical in understanding how genomic instability drives cancer, helping inform the company’s therapeutic development.
READ BIO
Jason Sheltzer, PhD
Scientific Advisor
Dr. Sheltzer’s research focuses on cancer genetics and identifying new therapeutic targets. His expertise in oncogene function and tumor vulnerabilities contributes to the scientific foundation of the company’s prevention strategies.
READ BIO
Jason Sheltzer, PhD
Scientific Advisor
Dr. Sheltzer’s research focuses on cancer genetics and identifying new therapeutic targets. His expertise in oncogene function and tumor vulnerabilities contributes to the scientific foundation of the company’s prevention strategies.
READ BIO
Alex Cagan, PhD
Scientific Advisor
Dr. Cagan’s work at the Sanger Institute explores how mutations accumulate in healthy tissues over time. His research helps shape strategies to slow or prevent the cellular changes that lead to cancer.
READ BIO
Alex Cagan, PhD
Scientific Advisor
Dr. Cagan’s work at the Sanger Institute explores how mutations accumulate in healthy tissues over time. His research helps shape strategies to slow or prevent the cellular changes that lead to cancer.
READ BIO
Matt Donne, PhD
Operational Advisor
Matt Donne brings deep experience in biotech operations, strategy, and planning. He has been deeply impactful in steering Permanence Bio through its early stages.
READ BIO
Matt Donne, PhD
Operational Advisor
Matt Donne brings deep experience in biotech operations, strategy, and planning. He has been deeply impactful in steering Permanence Bio through its early stages.
READ BIO
Eugene Kim, JD
Legal Advisor
Eugene Kim specializes in biotech law, guiding early-stage companies on corporate structuring, IP strategy, and regulatory compliance.
READ BIO
Eugene Kim, JD
Legal Advisor
Eugene Kim specializes in biotech law, guiding early-stage companies on corporate structuring, IP strategy, and regulatory compliance.
READ BIO
Protecting life
at its source.
This is the start of a long project. If you’re a scientist, clinician, investor, or advocate who wants to follow along or help, we’d like to hear from you.
© 2026 Permanence Bio
READ BIO
